6533b7dbfe1ef96bd127007a

RESEARCH PRODUCT

Analisi di costo-efficacia della vaccinazione universale in Italia con il vaccino Rix4414 contro i rotavirus.

B. StandaertCarla Maria ZottiAlfredo GuarinoElisabetta FrancoPier Luigi LopalcoG. Vitali RosatiBaroukh M. AssaelLucina TitoneA. MaroccoArturo TozziGiovanni GabuttiFederico MarchettiFranco Maria Ruggeri

subject

Pediatricsmedicine.medical_specialtybusiness.industryHealth PolicyRotavirusSettore MED/42 - Igiene Generale e ApplicatamedicineImmunization programPharmacology (medical)Health outcomesmedicine.disease_causebusiness

description

Objectives: Rotavirus (RV) is the most common etiological agent of gastroenteritis in children. The oral vaccine Rix4414 was recently commercialized in Italy for prevention of RV infections. The health outcomes and the economic impact of a national RV immunization program were assessed.

http://hdl.handle.net/2108/107232